Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study.

MLA

Nicolay, Jan P., et al. “Dimethyl Fumarate Treatment in Relapsed and Refractory Cutaneous T-Cell Lymphoma: A Multicenter Phase 2 Study.” Blood, vol. 142, no. 9, Aug. 2023, pp. 794–805. EBSCOhost, https://doi.org/10.1182/blood.2022018669.

APA

Nicolay, J. P., Melchers, S., Albrecht, J. D., Assaf, C., Dippel, E., Stadler, R., Wehkamp, U., Wobser, M., Zhao, J., Burghaus, I., Schneider, S., Gülow, K., Goerdt, S., Schürch, C. M., Utikal, J. S., & Krammer, P. H. (2023). Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study. Blood, 142(9), 794–805. https://doi.org/10.1182/blood.2022018669

Chicago

Nicolay, Jan P, Susanne Melchers, Jana D Albrecht, Chalid Assaf, Edgar Dippel, Rudolf Stadler, Ulrike Wehkamp, et al. 2023. “Dimethyl Fumarate Treatment in Relapsed and Refractory Cutaneous T-Cell Lymphoma: A Multicenter Phase 2 Study.” Blood 142 (9): 794–805. doi:10.1182/blood.2022018669.